If you’re dismissing psychedelics in pharma, think again. Stephanie Sirota and Connor Williams discuss overcoming stigma and regulatory challenges, and the results of a recent clinical trial that could signal a new era for mental health care.

PODCAST TEAM

Producer: Devon Leaver

Editor: Dominique Guerra

Featuring: Connor Williams, Senior Researcher at RTW Investments, moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments.

Stay tuned for a deep dive into psychedelics with the CEO of GH Research, Dr. Velichka (Villy) Valcheva, moderated by Connor Williams.

FOLLOW US

Love our podcast? Follow us on LinkedIn at RTW Investments, LP and check out our website for the latest updates and insights.

To make sure you never miss an episode, you can subscribe to the RTW podcast on Spotify, Apple Podcasts, Amazon Music, and most other podcast platforms.

CHAPTERS

00:00 - Introduction

00:21 - The development of psychiatric drugs

03:29 - Treatment resistant patients in the U.S. and the international market

05:50 - The need for new depression treatment drugs

08:05 - The rise of psychedelics & the impact of regulations and policies

13:58 - New areas of study in psychedelics

14:43- The valuation of psychedelics and what it means for investors

17:53 - Discovering GH Research and its novel approach to TRD

22:11 - Outro and disclaimer

DISCLAIMER

This interview was given by Connor Williams, Senior Researcher at RTW Investments, and moderated by Stephanie A. Sirota, Partner and Chief Business Officer at RTW Investments. Statements reflect RTW's views and opinions as of the date hereof and not as of any future date. All expressions of opinion are subject to change without notice and are not intended to be a forecast of future events or results. The views expressed by guests are their own, and their appearance on the program does not imply an endorsement of them or any entity they represent.